ADTX Stock Overview
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Aditxt, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.35 |
52 Week High | US$76.40 |
52 Week Low | US$2.31 |
Beta | 1.03 |
1 Month Change | -22.95% |
3 Month Change | -41.25% |
1 Year Change | -94.18% |
3 Year Change | -99.95% |
5 Year Change | n/a |
Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Aditxt gains on regaining compliance with Nasdaq listing requirements
Sep 29Aditxt climbs 32% postmarket after completing 1-for-50 reverse stock split
Sep 13Aditxt stock surges 61% on positive preclinical toxicity study of its psoriasis drug candidate
Jul 08Aditxt adds Lauren Chung to board of directors
Jun 18Aditxt, Todos Medical in distribution pact for for COVID-19 immune monitoring
Dec 14We Think ADiTx Therapeutics (NASDAQ:ADTX) Can Afford To Drive Business Growth
Nov 23Shareholder Returns
ADTX | US Biotechs | US Market | |
---|---|---|---|
7D | -25.4% | -4.2% | -3.7% |
1Y | -94.2% | -2.0% | 20.5% |
Return vs Industry: ADTX underperformed the US Biotechs industry which returned -1.7% over the past year.
Return vs Market: ADTX underperformed the US Market which returned 20.2% over the past year.
Price Volatility
ADTX volatility | |
---|---|
ADTX Average Weekly Movement | 10.9% |
Biotechs Industry Average Movement | 11.5% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.4% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ADTX's share price has been volatile over the past 3 months.
Volatility Over Time: ADTX's weekly volatility has decreased from 68% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2017 | 61 | Amro Albanna | www.aditxt.com |
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. It is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies.
Aditxt, Inc. Fundamentals Summary
ADTX fundamental statistics | |
---|---|
Market cap | US$4.61m |
Earnings (TTM) | -US$32.70m |
Revenue (TTM) | US$645.18k |
7.1x
P/S Ratio-0.1x
P/E RatioIs ADTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ADTX income statement (TTM) | |
---|---|
Revenue | US$645.18k |
Cost of Revenue | US$756.84k |
Gross Profit | -US$111.66k |
Other Expenses | US$32.59m |
Earnings | -US$32.70m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -16.67 |
Gross Margin | -17.31% |
Net Profit Margin | -5,068.49% |
Debt/Equity Ratio | 100.8% |
How did ADTX perform over the long term?
See historical performance and comparison